Video

Dr. Costa on the Patients Included in the OlympiA Trial in HER2- Breast Cancer

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

Ricardo Costa, MD, MSc, medical oncologist, Department of Breast Oncology, Clinical Investigator Track, Moffitt Cancer Center, discusses the patient population included in the phase 3 OlympiA trial (NCT02032823) in breast cancer.

Findings from the randomized OlympiA trial demonstrated a statistically meaningful improvement in disease-free survival with adjuvant olaparib (Lynparza) vs placebo in patients with BRCA1/2-mutant, HER2-negative, early-stage breast cancer. The large, multinational trial enrolled over 800 patients with germline pathogenic or likely pathogenic BRCA1/2 mutations. Patients were randomized 1:1 to treatment with one year of adjuvant olaparib or placebo, Costa says. 

Inclusion criteria for OlympiA stated that patients needed have a diagnosis of HER2–negative disease, Costa adds. Moreover, the majority of patients enrolled on the study had triple-negative breast cancer, Costa concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP